IL6 and cardiovascular disorder: Previously our group reported that Bazedoxifene could inhibit phosphorylation of STAT3 by targeting IL‐6/gp130 interface in pancreatic cancer cells,24 which implied the potential effect of Bazedoxifene on IL‐6/gp130 signalling in cardiovascular diseases.